An Observational Study on MabThera/Rituxan (Rituximab) in Patients With Chronic Lymphocytic Leukemia

Update Il y a 5 ans
Reference: NCT01178086

Woman and Man

  • | Country :
  • Germany
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This observational study will assess the therapeutic efficiency, the treatment schedules and handling procedures, and the safety profile of MabThera/Rituxan (rituximab) in routine care in patients with chronic lymphocytic leukemia. Data from patients will be collected for a total of 24 months.


Inclusion criteria

  • Lymphocytic Leukemia, Chronic

Links